Lumenis Introduces Medical Laser Training for Office-based ENT Physicians

Courses Designed to Help Physicians Respond to Anticipated Growth in Office-based Procedures

September 26, 2005 - Yokneam, Israel

Yokneam, Israel, September 26, 2005 – Lumenis^® Ltd. (LUME.PK), a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications, announced today the establishment of semi-annual medical laser courses tailored for ENT physicians practicing in an office environment. In the US, there are about 7,000 physicians in this category.

“Avner Raz, President and Chief Executive Officer of Lumenis, states, “Over the years, our lasers have proven effective and efficient for a number of procedures for the office-based otolaryngologist. Additionally, current market trends indicate more and more ENT procedures will be conducted in an office environment for potential healthcare cost savings and due to advances in technology, as well as the greater convenience offered to both physician and patient alike. Lumenis, with our depth and breadth of innovative technology, is ideally suited to meet the needs of this growing segment. At the same time, we continue to dominate the hospital laser market with our flagship UltraPulse SurgiTouch CO2 laser system.”

Yosef Krespi, MD, widely considered a pioneer and expert in ENT office-based laser procedures, will direct the course, entitled “Office-based Laser Surgery in Otolaryngology,” at St. Luke’s / Roosevelt Hospital Center in New York. According to Dr. Krespi, “Not many ENT physicians know about the versatility that lasers and newly-designed accessories can provide. They are very effective for tonsillotomies, turbinate reduction, tympanic membrane fenestration, uvulopalatoplasty, ablation of skin / mucosa lesions, etc., and a number of laryngeal applications in conjunction with laser waveguides. Coding and reimbursement will also be topics well covered in the course, since these have significant impact on practice decisions.”

Avner Raz added, “The world’s largest ENT meeting, the annual gathering of the American Academy of Otolaryngology – Head and Neck Surgery Foundation, is in Los Angeles this year from September 25-28. At this event, Lumenis plans to display and demonstrate our wide range of lasers and accessories for the office-based physician including its Compact class laser system. We will also officially introduce our Digital AcuBlade™ to the market. Our new AcuBlade System is an innovative robotic laser microsurgery system which allows the user to pre-select differently-shaped scanning patterns that result in precise, automated ablation or incision of delicate structures such as vocal cords – another exciting innovation from the world leader in medical lasers and light-based technologies.”

The next office-based ENT laser course is scheduled for October 7-8, 2005, in New York. Interested physicians may register by contacting Larry Perlstein at (212) 262-4444, or by completing the online registration form at www.surgical.lumenis.com/wt/content/meetings. Course dates for 2006 will be announced shortly.

About Lumenis

Lumenis is a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto www.lumenis.com.


Contact:

Lauri Hanover, CFO
1-866-232-6803
+972-4-959-9122

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, the implementation and outcome of its Turnaround Plan, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company's international operations and the Company's ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation and several securities class action lawsuits to which the Company is subject and the outcome of the investigation conducted by the Audit Committee; uncertainties relating to the Company’s continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.

Search

| Advanced Search| Site Map| Home